--- title: "FOXO4-DRI | PepTracker Pro" url: https://peptrackerpro.com/peptides/foxo4-dri description: "A senolytic peptide designed to selectively clear senescent cells by disrupting FOXO4-p53 interaction." lang: en --- Skip to main content **Educational information only.** This site does not provide medical advice. Read full disclaimer (https://peptrackerpro.com/disclaimer) **Research-only content.** This page is for educational purposes and does not constitute medical advice. Read full disclaimer → (https://peptrackerpro.com/research-disclaimer) # FOXO4-DRI Low Evidence A senolytic peptide designed to selectively clear senescent cells by disrupting FOXO4-p53 interaction. Aliases FOXO4-D-Retro-Inverso +1 more Evidence Low Evidence Last Updated 2026-06-16 Reading Time 2 min ## What It Is FOXO4-DRI is a D-retro-inverso peptide designed to disrupt the interaction between FOXO4 and p53 in senescent cells. By blocking this interaction, p53 is released to trigger apoptosis selectively in senescent cells while sparing healthy cells. A landmark 2017 mouse study showed improved fitness, fur density, and kidney function in aged mice. It represents a targeted approach to cellular senescence. In 2026 rankings of evidence-based anti-aging peptides, FOXO4-DRI entered the top 10 for the first time, reflecting growing preclinical evidence for selective senescent cell clearance. The senolytic approach — removing damaged cells rather than repairing them — is gaining traction as a complementary strategy alongside mitochondrial peptides (SS-31) and metabolic regulators (MOTS-c). As of early 2026, researchers continue to work on optimizing FOXO4-DRI and related senolytic peptides. Cleara Biotech, the company formed to commercialize the original Baar et al. research, remains a going preclinical concern focused on the FOXO4-p53 interaction as a therapeutic target. Side-by-side comparisons from the original study showed FOXO4-DRI cleared 70% of senescent cells with zero platelet count reduction, while navitoclax at equivalent senolytic efficacy dropped platelet counts by 40–60% — highlighting the peptide's selectivity advantage over small-molecule senolytics. No human trials have been initiated as of May 2026. Expanded in vitro work in 2026 using human chondrocytes confirmed selective removal of senescent cells while preserving healthy cell populations, supporting the peptide's potential for osteoarthritis and other joint-related degenerative conditions. Also known as: FOXO4-D-Retro-Inverso, Proxofim ## Evidence Snapshot Low Evidence Low Medium High | Study Type | Model | Outcome | Link | | --- | --- | --- | --- | | In vitro (human chondrocytes) | FOXO4-DRI selective senescent cell removal | Selectively removed senescent cells from expanded human chondrocytes while preserving healthy cells — relevant to osteoarthritis research | Source: https://pmc.ncbi.nlm.nih.gov/articles/PMC8116695/ | ## Commonly Discussed Benefits Longevity: https://peptrackerpro.com/benefits/longevity Anti-Aging: https://peptrackerpro.com/benefits/anti-aging Skin: https://peptrackerpro.com/benefits/skin Researching FOXO4-DRI? Track it, set reminders, and keep notes in the free app. Track in App (https://app.peptrackerpro.com/?add=foxo4-dri) ## Safety & Cautions - Only one major published animal study - No human clinical trials - Senolytic effects could theoretically impact healthy cells - Manufacturing complexity raises quality concerns - Not FDA-approved ## Comparisons See how FOXO4-DRI compares to related peptides: FOXO4-DRI vs Epithalon: https://peptrackerpro.com/compare/foxo4-dri-vs-epithalon FOXO4-DRI vs Klotho (Alpha-Klotho): https://peptrackerpro.com/compare/foxo4-dri-vs-klotho FOXO4-DRI vs MOTS-c: https://peptrackerpro.com/compare/foxo4-dri-vs-mots-c ## Calculator Tools Use our research tools to explore dosing and reconstitution data: Reconstitution Calculator: https://peptrackerpro.com/calculators ## Citations 1. [1] Baar MP. et al. — Targeted apoptosis of senescent cells restores tissue homeostasis. Cell. 2017 PubMed (https://pubmed.ncbi.nlm.nih.gov/28340339/) 2. [2] People Are Still Working on the Senolytic Peptide FOXO4-DRI — Fight Aging! 2026 PubMed (https://www.fightaging.org/archives/2026/02/people-are-still-working-on-the-senolytic-peptide-foxo4-dri/) ### Keep researching in the app - Log FOXO4-DRI to your private tracker - Set a dosing reminder - Compare it side-by-side with your stack Open PepTracker Pro Free: https://app.peptrackerpro.com/?add=foxo4-dri Browse more peptides: https://peptrackerpro.com/peptides ## Related Peptides ### Epithalon Low Evidence A tetrapeptide studied for its potential to activate telomerase and influence biological aging markers. Longevity: https://peptrackerpro.com/benefits/longevity Anti-Aging: https://peptrackerpro.com/benefits/anti-aging Sleep: https://peptrackerpro.com/benefits/sleep Immune Support: https://peptrackerpro.com/benefits/immune-support View Details: https://peptrackerpro.com/peptides/epithalon \+ Compare: https://peptrackerpro.com/compare?select=epithalon Track in App: https://app.peptrackerpro.com/?add=epithalon ### Klotho (Alpha-Klotho) Low Evidence A naturally occurring longevity hormone (secreted alpha-klotho) being studied for cognition and brain aging; a single low-dose injection improved memory in aged monkeys, and a first-in-human Phase 1 trial in older adults is underway. Cognition: https://peptrackerpro.com/benefits/cognition Neuroprotection: https://peptrackerpro.com/benefits/neuroprotection Anti-Aging: https://peptrackerpro.com/benefits/anti-aging Longevity: https://peptrackerpro.com/benefits/longevity View Details: https://peptrackerpro.com/peptides/klotho \+ Compare: https://peptrackerpro.com/compare?select=klotho Track in App: https://app.peptrackerpro.com/?add=klotho ### MOTS-c Low Evidence A mitochondrial-derived peptide studied for metabolic regulation, exercise mimetic effects, and longevity. Metabolism (https://peptrackerpro.com/benefits/metabolism)Fat Loss (https://peptrackerpro.com/benefits/fat-loss)Longevity (https://peptrackerpro.com/benefits/longevity)Muscle Growth (https://peptrackerpro.com/benefits/muscle-growth)+2 more View Details: https://peptrackerpro.com/peptides/mots-c \+ Compare: https://peptrackerpro.com/compare?select=mots-c Track in App: https://app.peptrackerpro.com/?add=mots-c ## Structured data ```json [ { "@context": "https://schema.org", "@type": "Organization", "name": "PepTracker Pro", "url": "https://peptrackerpro.com", "logo": "https://peptrackerpro.com/favicon.png", "description": "Evidence-based educational resource dedicated to improving peptide research literacy.", "contactPoint": { "@type": "ContactPoint", "email": "hello@peptrackerpro.com", "contactType": "customer support" }, "sameAs": [] }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "FOXO4-DRI", "description": "A senolytic peptide designed to selectively clear senescent cells by disrupting FOXO4-p53 interaction.", "url": "https://peptrackerpro.com/peptides/foxo4-dri", "lastReviewed": "2026-06-16", "reviewedBy": { "@type": "Organization", "name": "PepTracker Pro Research Team", "url": "https://peptrackerpro.com" }, "isPartOf": { "@type": "WebSite", "name": "PepTracker Pro", "url": "https://peptrackerpro.com" } }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://peptrackerpro.com" }, { "@type": "ListItem", "position": 2, "name": "Peptides", "item": "https://peptrackerpro.com/peptides" }, { "@type": "ListItem", "position": 3, "name": "FOXO4-DRI", "item": "https://peptrackerpro.com/peptides/foxo4-dri" } ] }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "People following senolytic research?", "acceptedAnswer": { "@type": "Answer", "text": "FOXO4-DRI is a research peptide studied in preclinical models. A senolytic peptide designed to selectively clear senescent cells by disrupting FOXO4-p53 interaction." } }, { "@type": "Question", "name": "Those interested in cellular senescence science?", "acceptedAnswer": { "@type": "Answer", "text": "FOXO4-DRI is a research peptide studied in preclinical models. A senolytic peptide designed to selectively clear senescent cells by disrupting FOXO4-p53 interaction." } }, { "@type": "Question", "name": "Individuals exploring cutting-edge longevity interventions?", "acceptedAnswer": { "@type": "Answer", "text": "FOXO4-DRI is a research peptide studied in preclinical models. A senolytic peptide designed to selectively clear senescent cells by disrupting FOXO4-p53 interaction." } } ] } ] ```